Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial

Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial

Abstract Background High dose vasopressors portend poor outcome in vasodilatory shock. We aimed to evaluate the impact of baseline vasopressor dose on outcomes in patients treated with angiotensin II (AT II). Methods Exploratory post-hoc analysis of the Angiotensin II for the Treatment of High-Outpu...

Full description

Bibliographic Details
Main Authors: Patrick M. Wieruszewski, Rinaldo Bellomo, Laurence W. Busse, Kealy R. Ham, Alexander Zarbock, Ashish K. Khanna, Adam M. Deane, Marlies Ostermann, Richard G. Wunderink, David W. Boldt, Stew Kroll, Chuck R. Greenfeld, Tony Hodges, Jonathan H. Chow, the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Critical Care
Subjects:
Angiotensin
Shock
Vasopressor
Catecholamine
Multimodal
Outcomes
Online Access:https://doi.org/10.1186/s13054-023-04446-1

Internet

https://doi.org/10.1186/s13054-023-04446-1

Similar Items